Clinical Trial Update: Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compares Pradaxa (dabigatran etexilate) to warfarin for preventing recurrent venous thromboembolism in patients with angiographically c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)
• Warfarin (warfarin)

Snippet

Sponsor: Meshalkin Research Institute of Pathology of Circulation | Conditions: Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy | Phase 4 | Status: UNKNOWN